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The lack of progress over the last decade in developing treatments for Alzheimer’s disease has called into question
the quality of the cognitive assessments used while also shifting the emphasis from treatment to prophylaxis by
studying the disorder at earlier stages, even prior to the development of cognitive symptoms. This has led various
groups to seek cognitive tests which are more sensitive than those currently used and which can be meaningfully
administered to individuals with mild or even no cognitive impairment. Although computerized tests have long
been used in this field, they have made little inroads compared with non-automated tests. This review attempts to
put in perspective the relative utilities of automated and non-automated tests of cognitive function in therapeutic
trials of pathological aging and the dementias. Also by a review of the automation of cognitive tests over the last
150 years, it is hoped that the notion that such procedures are novel compared with pencil-and-paper testing will
be dispelled. Furthermore, data will be presented to illustrate that older individuals and patients with dementia are
neither stressed nor disadvantaged when tested with appropriately developed computerized methods. An important
aspect of automated testing is that it can assess all aspects of task performance, including the speed of cognitive
processes, and data are presented on the advantages this can confer in clinical trials. The ultimate objectives of the
review are to encourage decision making in the field to move away from the automated/non-automated dichotomy
and to develop criteria pertinent to each trial against which all available procedures are evaluated. If we are to make
serious progress in this area, we must use the best tools available, and the evidence suggests that automated testing
has earned the right to be judged against the same criteria as non-automated tests.Introduction
Cognitive dysfunction characterizes all of the dementias,
and as a result cognitive testing is an essential element
of all research in this field. Although numerous automated
tests of cognitive function have long been available, the
utilization of such procedures in clinical trials in the fields
of pathological aging and dementia has not been wide-
spread. Instead, the overwhelming majority of procedures
currently employed are non-automated, many having been
originally developed for use in clinical neuropsychology.
This is exemplified by the Alzheimer’s Disease Assessment
Scale-Cognitive subtest (ADAS-Cog), which has been theCorrespondence: keith@wesnes.com
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proved drugs for Alzheimer’s disease (AD) [1] and in the
trial upon which the US Food and Drug Administration
(FDA) approved the first therapy for Parkinson’s disease
dementia (PDD) [2].
During the last decade, the news from this field has been
overwhelmingly negative; no new treatment has been ap-
proved for AD, despite a massive worldwide research effort
which has been overshadowed by the failure of well over
100 putative treatments [3,4]. This depressing experience
has had two consequences relevant to this article. First, the
ADAS-Cog has come under scrutiny for its effectiveness
as an outcome measure in such trials, owing in part to
failures to detect time-based declines in untreated patients
[5], although other limitations have long been recognized
(for example, [6,7]). Second, in recent years, the focus of
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the disease [3,8-10], areas in which the ADAS-Cog would
have limited, if any, utility. As a consequence, a number of
recent workgroups and consensus meetings had concluded
that other more sensitive and appropriate assessments of
cognitive function are required in the field [1,9,11,12]. For
instance, in 2010, the National Institute on Aging and the
Alzheimer’s Association convened a workshop to discuss
state-of-the-art methods for cognitive assessment, including
computerized batteries, and new approaches under devel-
opment [1]. The following quotes from the article set the
scene for this review:
‘Computerized batteries offer a number of advantages
over paper-and-pencil type tests, notably precise,
accurate assessments that can be obtained with
millisecond timing, ease of administration
(sometimes with no administrator needed) and
scoring, greater standardization, and adaptive
presentation of items’.
‘Important disadvantages of computerized testing in
older adults are that these tests can be challenging for
people with visual limitations; they can be too
fast-paced or difficult for people who are unfamiliar
with computers; and participants may have problems
adapting to a keyboard, mouse, or number pad’.
‘Yet more data are needed before computerized
batteries can take the place of traditional assessments
for clinical decision-making purposes. In addition,
some people (both examiners and examinees) will just
feel more comfortable with paper-and-pencil tests
than computer-based batteries’.
The purpose of this review, as the title implies, is not
to add fuel to the fire by arguing the relative merits of
computerized testing over non-automated methods, but
rather to attempt to level the playing field in order that
tests, whether automated or not, will in the future be
evaluated against a common set of criteria to determine
their usefulness in clinical trials. As pointed out by Black
and colleagues [12], ‘there must be a strategy to selecting
a scale so that it measures what it is intended to measure.
Whether the best measure turns out to be computer-based
or pen-and-paper is then secondary’.
Historical perspective
‘Pencil and paper’ tests, as in the quotation above and
elsewhere (for example, [13]), are frequently termed
‘traditional’ in comparison with automated procedures.
However, a pertinent and not widely recognized point
is that automation of many of the cognitive tasks in
use today preceded the development of the vast major-
ity of tests used in clinical neuropsychology as well asthe ADAS-Cog and Mini-Mental State Examination
(MMSE) [14]. This mischaracterization of many com-
puterized tests as ‘new kids on the block’ serves to
undermine them, implying that they are ‘a work in
progress’ or ‘experimental in nature’ or ‘have not yet stood
the test of time’.
Electromechanical solutions
In 1868, Franciscus Donders launched the field of
‘mental chronometry’ by developing the original versions
of two now widely recognized tests: simple reaction time
and choice reaction time (CRT) [15]. He devised and used
the ‘noematachograph’, an instrument involving a helically
moving horizontal cylinder mounted with ebonite and
brass disks, electrodes, and a tuning fork. This ingenious
apparatus could record the time lag between a stimulus
(colored light, letter-symbol, or sound) and either manual
or vocal responses. He demonstrated that CRTs were
longer than simple reaction times, reflecting the extra
information processing necessary to perform CRT, a finding
which remains one of the central tenets of cognitive neuro-
science. Since then, these tests, together with other assess-
ments, including vigilance tasks, have been the mainstay of
attention testing in cognitive neuroscience [16].
In 1919, the American Committee for the Study of
the Tobacco Problem commissioned an investigation
entitled ‘Tobacco and Mental Efficiency’. This program
was led by the experimental psychologist Clark L Hull
at the University of Wisconsin [17]. Hull, renowned for
his experimental rigor and sophisticated approach to
test validation [18], devised a series of cognitive tests to
measure the effects of tobacco smoking on both smokers
and non-smokers. One of the tests involved the speed
with which visually presented four-letter words could be
vocalized. Another involved the formation of connections
between visually presented shapes and the vocalization of
nonsense syllables, which today would be termed paired-
associate learning. The sophistication of the instrumenta-
tion is illustrated by the following:
‘The reaction-time was measured by a Johns Hopkins
chronoscope controlled by a tuning fork of special
construction. The rate of this fork was calibrated
against a Jaquet chronograph. It was such that the
units of the chronoscope readings were 0.0034 of a
second or approximately 1/300th. The chronoscope
was connected electrically with the exposure
apparatus in such a way that the instant a word came
into view, the timing part of the chronoscope was
automatically set going. When the subject spoke the
word, a sensitive voice key automatically stopped it’.
Thus, over 90 years ago, a procedure had been devel-
oped to measure oral reaction times with a precision of
Wesnes Alzheimer's Research & Therapy 2014, 6:58 Page 3 of 8
http://alzres.com/content/6/5/583.4 milliseconds, something not achieved in many cur-
rently available tests. This early clinical trial demon-
strated that Hull’s methodology was sufficiently sensitive
to detect cognition enhancement, and tobacco adminis-
tration was found with a ‘fair probability’ to produce an
improvement in speed on the reading reaction time and
paired-associate learning tasks.
A range of other tests were developed in the middle of
the last century. In 1948, Norman Mackworth developed
a prolonged visual vigilance task to simulate monitoring a
radar screen [19], which was shown to be sensitive to the
effects of amphetamine [20], cigarette smoking, and nico-
tine tablets [21]. In 1956, Rosvold and colleagues [22] first
described the continuous performance test (CPT), a para-
digm in wide use today. It was used to study attention defi-
cits in brain-damaged patients, and the motivation for
developing the test was that current non-automated tests of
attention, such as the Wechsler digit span and digit symbol
substitution subtests, had ‘not consistently showed decline
following brain damage’ [22]. The stimuli were letters pre-
sented on a rotating drum via a visor, a response key being
mounted to the right. The authors concluded that brain-
damaged patients had poorer performance on this task re-
quiring continuous attention, and in 1959 the drug sensitiv-
ity of the CPT was confirmed [23]. Two other examples of
electromechanical tests were developed in the early 1950s:
(1) the Bakan test, a 48-minute sustained attention task in
which a series of digits was presented via headphones at
the rate of one per second, the participant having to detect
sequences of three consecutive odd digits [24]; and (2) the
pursuit rotor task, which involved using a stylus to follow a
small disc of light on a turntable rotating at one revolution
per second [25].
Computerized cognitive tests
One of the pioneers in using the early computers to run
cognitive tests was John Gedye, who demonstrated that
such procedures could usefully assess the cognitive deficits
in patients with brain damage and dementia [26]. All of the
tasks described in the previous section have since been
computerized over the last 50 to 60 years; the sensitivity of
the Mackworth clock, CPT, and Bakan (now widely known
as the rapid visual information processing task) have been
enhanced by the additional collection of reaction times.
The early laboratory computers were also used to develop
new procedures such as the still widely employed memory
scanning task [27]. The field really started to progress with
the advent of the microcomputer in 1977 and the personal
computer in the early 1980s. Since then, a huge variety of
computerized tests and test systems have been developed
and used widely in cognitive neuroscience and clinical trials
(for example, [28,29]), and many have been specifically de-
signed to assess patients with mild cognitive impairment
(MCI) and AD (for example, [1,12,30,31]).Problems with computerized tests
Widely expressed potential downsides of computerized
testing of older patients center on the capability of such
individuals to operate computers and on the acceptability
of such ‘novel’ procedures including the potential anxiety
and stress individuals may experience when confronted
with complex-looking equipment [1]; of course, it should
be accepted that test anxiety has long been associated with
non-automated tests [32,33].
Sano [34] was one of the first researchers to recognize
that attention deficits were prevalent in diseases of aging,
including AD and Parkinson’s disease. A computerized
two-choice reaction time task was developed for use by
‘mildly impaired’ patients with AD. Sano recognized the ad-
vantages of using a personal computer, including consistent
presentation of task information, ease and accuracy of re-
cording responses, and rapid data analysis. Given the era, it
was acknowledged that the participants needed to become
comfortable with the testing procedures; and the benefits
were recognized of having the tasks explained and demon-
strated by an administrator, as opposed to the participant
having to follow on-screen instructions. Further require-
ments were having the on-screen stimuli presented at the
size necessary to overcome any visual difficulties and for
the responses to be simple and not require excessive
strength. The benefits of practice on the task were acknowl-
edged, and providing extra practice to prevent slower learn-
ing due to memory problems of the participants was
required. The procedure was successfully implemented,
and reaction time was found to be slower in older healthy
participants than young participants and to be slowest of all
in the AD group. The data permitted the conclusion that
patients with AD have deficits to selective attention.
Frydenberg [35] reported on the utilization of the micro-
computer in rehabilitation programs for older patients,
which had begun in her institution in 1981. On the issue
of whether there would be fear, resistance, or an inability
to master the necessary skills, Frydenberg reported an
overwhelmingly positive response by the patients. A simi-
lar response was seen in an early memory clinic evaluation
of a computerized cognitive test system. The study estab-
lished that dementia patients who were up to 94 years old
and who had MMSE scores of as low as 6 could be tested
satisfactorily [36]. The test system collected patient re-
sponses solely from a response box with two buttons,
and previous development had determined optimal sizes
and rates of presentation for the experimental stimuli.
Two quotes from the article are revealing:
‘The utility of the testing in this population was very
satisfactory, supported by the impression of the
psychologist who administered the tests that patients
of all abilities generally enjoyed performing the
system… more than the other tests, many commenting
http://alzres.com/content/6/5/58
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another occasion’.
‘The clinic staff were surprised at the extent to which
physically disabled patients including those with
Parkinson’s disease and post-stroke patients were able
to manage the response buttons’.
Another study, in a group of individuals who were at least
85 years old, sought to compare the relative acceptability of
computerized tests administered via a tablet - simple
reaction time (SRT), CRT, a vigilance task, and episodic
verbal recognition - with ‘traditionally’ administered
neuropsychological tests (the Wechsler digit symbol
substitution word-list recall and word recognition tests)
[37]. Testing was conducted in the homes of the partici-
pants, and it was found that only 91% could complete the
neuropsychological tests but that 100% completed the
computerized ones. The participants randomly assigned
to computerized tests were significantly less likely to rate
the tests as difficult, stressful, or unacceptable than those
randomly assigned to pencil-and-paper tests. Researchers
were also significantly less likely to rate participants as
being distressed in the computer test group.
Although the above studies demonstrate that computer-
ized testing can be acceptable to older patients and patients
with dementia, are some methodologies more acceptable
than others? One study contrasted two computerized
cognitive test systems administered over the course of a
6-month period to AD patients who were up to 100 years
old [38]. One, the Cognitive Drug Research (CDR) System,
involved responses being made via a response box, and
the other, the CANTAB (Cambridge Neuropsychological
Test Automated Battery) System, involved the use of a
touch screen. The study was unable to collect enough data
on the latter test system because of difficulties, including
unacceptability by the patients and problems with data
storage, with the result that the research article on the
study was based entirely on the findings of the CDR
System. Another study, contrasting the cognitive deficit
profiles of dementia with Lewy bodies (DLB) patients with
AD patients, switched from the CANTAB System to
the CDR System [39]. This was due to 90% of succes-
sive patient referrals being excluded from CANTAB
testing because of problems with the procedural com-
plexity, duration, nature, and the overall acceptability
of the methods. In contrast, ‘the CDR battery used was
specifically designed (Simpson et al., [36] 1991) for use
with a demented population and this is reflected in the
high (70%) inclusion rate of consecutively referred
cases’ [39]. Various factors were cited as relevant to
this higher utility, including the ability to temporarily
pause tasks if patients became fatigued or distracted,
the large size of the stimuli employed which minimizedthe impact of visual disturbances on task performance,
the absence of any negative feedback about poor per-
formance, and the brief nature of the tests. In contrast,
only 30% of patients were excluded from being evalu-
ated with the CDR System. Clearly, some methods of
implementing automated cognitive testing to patients
with dementia can prove unacceptable.
Other perceived limitations of computerized tests in the
field of dementia may be the lack of regulatory acceptance
of such procedures. In terms of regulatory precedent, in
1992, the FDA approved a computerized cognitive test sys-
tem as the primary outcome variable in two pivotal phase
III studies of the effects of D-Cycloserine in AD [40].
Strengths of computerized tests
This section from a position paper published in 1997 by
the International Working Group on Harmonization of
Dementia Drug Guidelines [31] is pertinent:
‘Computerized procedures currently are used
extensively in general psychopharmacology, and some
systems have been developed specifically for use with
demented patients. There is evidence that, after an
initial familiarization, properly implemented
computerized procedures can be perfectly acceptable
to AD patients (Ferris et al., 1988; Simpson et al., 1991).
Automated testing can have clear advantages for clinical
trials in this field. The task information always is
presented in a standard fashion; the recording of
responses is done automatically and precisely, without
any bias; and there are no grey areas involving
differences in interpretation. These advantages can
reduce variability both from session to session for a
patient, and also between different national and
international sites. Automated procedures recently have
been shown to be more sensitive than the standard tests
that are used extensively in this field (Mohr et al., 1996),
and the sensitivity to anticholinesterases in patients with
AD also has been established (Siegfried, 1993). Given the
previously noted importance of assessing attention and
processing speed in patients with AD, computerized
tests can provide optimal procedures for assessing
changes in these functions (for example, Wesnes et al.,
1987; Nicholl et al., 1995). Some tests of attention such
as vigilance can be run only on computers. However,
before being used in major trials, extensive assessments
of reliability, validity, and utility of these tests must be
made. In addition to the aforementioned basic test
criteria, crucial requirements for automated testing
include the recording of responses via simple response
buttons or touch screens, not the keyboard; absence of
unwanted negative feedback from the tasks; timing
routines that are accurate to the nearest millisecond and
that are made independently of the internal clocks of the
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hardware; presentation of information using specially
constructed fonts that are clearly visible to patients
with AD, and security of automatically recorded data
files that can be accessed only by authorized site staff
members. The Work Group concluded that
computerized procedures initially should be used
together with the established procedures in the field
(for example, the ADAS) so that the comparable utility
and sensitivity of the two types of testing can be
identified. If clear advantages of computerized
procedures are demonstrated, such procedures might
supersede existing methods’.
It should be noted that one of the authors of this article
helped to develop the ADAS-Cog.
One of the more important advantages of automated
testing is the comprehensive evaluation of task perform-
ance. A study found patients with MCI to have accuracy
scores on working memory and episodic recognition tasks
which were the same as those of non-impaired individuals;
yet when the speed of the responses in the tasks was eval-
uated, deficits which approached or reached the levels of
patients with dementia were found [41]. In regard to these
findings, the authors commented:
‘It may be that patients in this group are aware of
some deficit and know that, in a variety of situations,
they have to work more slowly in order to achieve
their main aim—the correct answer—a trade-off
between accuracy and speed. Alternatively, they may
have a deficit in the speed with which they can
recognize and process information, although their
accuracy of recognition is not much impaired. Thus,
the speed of memory performance may be the first
aspect of the memory system to decline as the system
begins to fail. Other factors such as confidence and
certainty may also be important’ [41].
Whatever the reason for this interesting finding, it
would clearly have gone unnoticed with non-automated
testing of working and recognition memory. Assessing re-
action times on attention tasks has also been beneficial;
for example, Ballard and colleagues [42] were able to
discriminate DLB and PDD patients from AD patients
on the basis of a selective prolongation of CRT in relation
to SRT as well as an increase in the variability of reaction
times. These differences reflected the bradyphrenia and
fluctuating attention which are seen in DLB and PDD [43]
and supported an earlier finding using computerized test-
ing which identified bradyphrenia in Parkinson’s disease
as being possibly related to dementia [44]. Mohr and
colleagues [6] found computerized testing to be super-
ior in correctly classifying patients to have either ADor Huntington’s disease in comparison with the ADAS-Cog,
MMSE, Mattis Dementia Rating Scale, and the Wechsler
Memory Scale. Furthermore, they found computerized
testing to be best able to discriminate the two dementias.
This more sophisticated profiling of cognitive dysfunction
also confers benefits in the evaluation of drug therapy,
one study enabling a fuller profile of benefits to be estab-
lished than would be seen using neuropsychological tests
[45], while another differentiated two of the registered an-
ticholinesterases in AD patients on the basis of their rela-
tive effects on attention [46].
Can automation improve sensitivity in long-term clin-
ical trials? One study evaluated the effects of an angio-
tensin II-receptor blocker on cognitive function over the
course of 5 years in a population of 257 hypertensive,
but not cognitively impaired, older adults with a mean
age of 76 years [47]. It was found that, on computerized
measures of episodic memory and attention, active treat-
ment statistically significantly reduced the rate of decline
seen under placebo over the 5-year period with effect
sizes comparable to those seen with anticholinesterases
in AD [48]. On the other hand, the neuropsychological
tests used in this study did not identify any benefit
(Trail Making test, Category Fluency, and Verbal Fluency).
It should be noted that the overall study methodology and
population in this study were comparable to those of trials
in preclinical AD, suggesting that appropriate computer-
ized testing will at the minimum be no less sensitive than
neuropsychological tests.
Two recent examples illustrating the utility of automated
testing in therapeutic clinical trials of pathological aging are
relevant. Newhouse and colleagues [49] found automated
testing, including the CPT, to help identify beneficial effects
of nicotine over the course of 6 months in amnestic MCI,
one of the few successful studies in this condition. A phase
II study of a potent and selective alpha-2C adrenoceptor
antagonist in 100 patients with moderate to moderately
severe AD identified reliable benefits of the compound
over the course of a 3-month period using a computer-
ized test system [50]. On the basis of these results, a
successful license agreement for the development and
commercialization of the product has just been established
with a partner company [51].
Relative costs of using automated versus
non-automated tests in clinical trials
It is worthwhile to consider the relative economics of
the two types of testing. Certainly, there is a greater
initial capital investment in providing study sites with
computers. However, training the staff to administer
automated and non-automated tests will require a compar-
able investment of time, and most computerized systems
can be administered by non-specialist staff, whereas
most neuropsychological tests need to be administered
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require manual scoring and data entry, which can be
time-consuming and subject to human error, whereas
the vast majority of computerized tests automatically
record and score the data, and the study database is
built up with relatively little staff involvement. Most
tests, whether automated or not, are subject to license
fees, and thus the overall costs to trials tend to balance
out between the two methodologies, the higher initial
outlay for providing computers being offset by the sub-
sequent saving of time and personal involvement in
data capture, scoring, and entry into the study database.
Furthermore, the opportunities discussed later for remote
data capture (for example, via the internet) can greatly re-
duce the costs and effort involved in test administration
and data acquisition.
Current status and future developments of the
automation of cognitive tests
It should be clear from this review that automated tests
have long been available for use in clinical trials in
pathological aging and that a wide variety of systems are
currently available. Various opportunities for gathering
cognitive function data outside of the clinic or labora-
tory have also been explored. Since the start of the mil-
lennium, groups have conducted cognitive tests via a
variety of remote platforms: via the telephone using
interactive voice response technology [52], via cell phones
(for example, [53]), and via the internet [54]. Furthermore,
many neuropsychological tests have been computerized
(for example, [55]), and digital pens enable any pencil-
and-paper test to be automated (for example, [56]). Other
developments have included virtual reality testing in AD
patients [57] and cognitive testing embedded in games
[58]. A computerized version of ADAS-Cog has also been
developed and has been shown to have greater reliability
than the original version [59]. However, to the knowledge
of the author, this version has not been used in major clin-
ical trials in the 3 years since that article appeared.
Conclusions
A major thrust of this review has been that the fundamen-
tal requirements for computerized tests in terms of utility,
reliability, validity, and sensitivity are no different from
those for any other form of cognitive testing. Once these
crucial properties are satisfactorily established for any test
or test system, the overwhelming attribute which should
drive test selection for therapeutic trials is the ability to re-
liably and sensitively measure change over time. The latter
use of ‘reliably’ means that the test scores should reflect
the cognitive abilities of the individual at each assessment
time, not changes due to practice effects or noise in the
assessment. Sensitivity, of course, means that any change,
positive or negative, should be detectable with the highestpossible levels of precision. There has been some historic
prejudice toward highly sensitive measures, primarily in
terms of the detection of changes which have little conse-
quence to everyday life. However, over recent years, the
reporting of effect sizes, such as in Cohen’s d, has become
almost standard practice, thus enabling highly statistically
reliable but trivial effects to be differentiated from effects
of clinical and everyday relevance.
The present review has been an opportunity for the
author to revisit a question posed 15 years ago:
‘The purpose of this chapter is to shed some light
upon the intriguing question of why, for decades,
some researchers have gone to such incredible lengths
to harness the latest technological advancements of
the day in order to automate tests of mental
capabilities, while their colleagues have been perfectly
happy to make such assessments simply using pencil,
paper and sometimes also a stopwatch?’ [14].
It is hoped that the reader will now have a better under-
standing of the factors behind this interesting dichotomy
and also that this review has convincingly illustrated that
automated testing is by no means novel and that, with ap-
propriate implementation, it can stand shoulder to shoulder
with pencil-and-paper testing in terms of acceptability,
utility, reliability, validity, and sensitivity. The intention
has been to make the case in the strongest possible fashion
that, for any particular trial, criteria should be established
for the essential requirements of cognitive assessment to
achieve the aims of the study and for these then to be ap-
plied evenly to all potential instruments available, whether
they be computerized or pencil and paper.
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